Section Edited by Aude Chapuis, MD and Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
ICOS-expressing CAR-T cells mediate durable eradication of triple-negative breast cancer and metastasisLixue Cao, Haojie Peng, Yanzhen Chen, Baijin Xia, Tao Zeng, Jialing Guo, Fei Yu, Haiyan Ye, Hui Zhang, Xinxin Chen
11 November 2024
In situ endoscopic photodynamic therapy combined with immature DC vaccination induces a robust T cell response against peritoneal carcinomatosisCharline Degavre, Anouk Lepez, Sebastien Ibanez, Clémence François, Katarzyna Głowacka, Céline Guilbaud, Florine Laloux-Morris, Hrag Esfahani, Davide Brusa, Caroline Bouzin, Olivier Feron
5 November 2024
Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cellsMin Wu, Ling Mao, Xuejia Zhai, Jie Liu, Junhan Wang, Langhong Li, Jiangjie Duan, Jun Wang, Shuang Lin, Jianjun Li, Shicang Yu
21 October 2024
NSGS mice humanized with cord blood mononuclear cells show sustained and functional myeloid–lymphoid representation with limited graft-versus-host diseaseCarla Panisello, Rosario Aschero, Alba Martinez-Moreno, Heleia Roca Ho, Aida Falgas, Europa Azucena González-Navarro, Julieta Carabelli, Edwards Pradenas, María Lázaro-Díez, Julia G Prado, Julià Blanco, Jorge Carrillo, Manel Juan, Ángel M Carcaboso, Clara BuenoSee the full list of authors
7 October 2024
Antigen-independent activation is critical for the durable antitumor effect of GUCY2C-targeted CAR-T cellsChangsong Qi, Dongqun Liu, Chang Liu, Xiaofei Wei, Mingyang Ma, Xinan Lu, Min Tao, Cheng Zhang, Xicheng Wang, Ting He, Jian Li, Fei Dai, Yanping Ding, Lin Shen
4 October 2024
Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapyJessie S Kroonen, Anne K Wouters, Ilona J de Graaf, Dennis F G Remst, Sumit Kumar, Tassilo L A Wachsmann, Amina F A S Teunisse, Jessica P Roelands, Noel F C C de Miranda, Marieke Griffioen, Mirjam H M Heemskerk, Alfred C O Vertegaal
26 September 2024
Neurofilament light chain levels as an early predictive biomarker of neurotoxicity after CAR T-cell therapyMarion Larue, Amélie Bouvier, Alexis Maillard, Alexis Cuffel, Vincent Allain, Renata Ursu, Antoine F Carpentier, Elie Azoulay, Catherine Thieblemont, Roberta Di Blasi, Sophie Caillat-Zucman
24 September 2024
BCMA-BBZ-OX40 CAR-T Therapy Using an Instant Manufacturing Platform in Multiple MyelomaTing Wang, Yazi Yang, Lie Ma, Ru Feng, Jiangtao Li, Chunli Zhang, Jiefei Bai, Yanping Ding, Guanghua Liu, Fei Wu, Xinan Lu, Shi Feng, Zhenling Li, Ting He, Jian LiSee the full list of authors
23 September 2024
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapyWen Luo, Hai Hoang, Hongwen Zhu, Katherine Miller, Xiaokui Mo, Shiori Eguchi, Meijuan Tian, Yanling Liao, Janet Ayello, Jeremy M Rosenblum, Mario Marcondes, Mark Currier, Elaine Mardis, Timothy Cripe, Dean LeeSee the full list of authors
12 September 2024
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirusStefan Barisic, Elizabeth M Brahmbhatt, Elena Cherkasova, Timothy T Spear, Ujjawal Savani, Stephanie Pierre, Gina M Scurti, Long Chen, Muna Igboko, Rosa Nadal, Gang Zeng, Gordon Parry, David F Stroncek, Steven Highfill, Annika V DalheimSee the full list of authors
11 September 2024